Fundamental Analysis of FOGHORN THERAPEUTICS INC(NASDAQ:FHTX) stock

Fundamental Rating

FHTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. FHTX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, FHTX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

FHTX had negative earnings in the past year.

FHTX had a negative operating cash flow in the past year.

In the past 5 years FHTX always reported negative net income.

FHTX had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -29.58%, FHTX is doing good in the industry, outperforming 68.85% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-29.58%
ROE	N/A
ROIC	N/A

ROA(3y)-26.94%

ROA(5y)-67.4%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FHTX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FHTX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, FHTX has more shares outstanding

Compared to 5 years ago, FHTX has more shares outstanding

There is no outstanding debt for FHTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -2.07, we must say that FHTX is in the distress zone and has some risk of bankruptcy.

FHTX's Altman-Z score of -2.07 is in line compared to the rest of the industry. FHTX outperforms 53.10% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-2.07

ROIC/WACCN/A

WACC11.78%

2.3 Liquidity

A Current Ratio of 4.77 indicates that FHTX has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 4.77, FHTX is in line with its industry, outperforming 52.39% of the companies in the same industry.

FHTX has a Quick Ratio of 4.77. This indicates that FHTX is financially healthy and has no problem in meeting its short term obligations.

FHTX's Quick ratio of 4.77 is in line compared to the rest of the industry. FHTX outperforms 53.98% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.77
Quick Ratio	4.77

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

FHTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.95%, which is quite impressive.

The Revenue for FHTX has decreased by -21.66% in the past year. This is quite bad

Measured over the past years, FHTX shows a very strong growth in Revenue. The Revenue has been growing by 329.86% on average per year.

EPS 1Y (TTM)21.95%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%8.82%

Revenue 1Y (TTM)-21.66%

Revenue growth 3Y329.86%

Revenue growth 5YN/A

Sales Q2Q%-55.33%

3.2 Future

Based on estimates for the next years, FHTX will show a small growth in Earnings Per Share. The EPS will grow by 4.13% on average per year.

FHTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.54% yearly.

EPS Next Y25.75%

EPS Next 2Y15.8%

EPS Next 3Y9.65%

EPS Next 5Y4.13%

Revenue Next Year-12.82%

Revenue Next 2Y-0.53%

Revenue Next 3Y4.99%

Revenue Next 5Y28.54%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FHTX. In the last year negative earnings were reported.

Also next year FHTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y15.8%

EPS Next 3Y9.65%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

FHTX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

FOGHORN THERAPEUTICS INC

NASDAQ:FHTX (12/18/2024, 3:43:22 PM)

4.855

-0.65 (-11.89%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap269.89M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-29.58%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.08

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.77
Quick Ratio	4.77
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)21.95%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y25.75%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-21.66%

Revenue growth 3Y329.86%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

FOGHORN THERAPEUTICS INC (FHTX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens